SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                   FORM 10QSB/A


                  Quarterly Report under Section 13 or 15(d) of
                       the Securities Exchange Act of 1934


For Quarter Ended                           Commission File Number
-----------------                           ----------------------

September 30, 2000                                      000-28519




                          PATHOBIOTEK DIAGNOSTICS, INC.
                                   (New Name)
                            -------------------------
                           INVESTRA ENTERPRISES, INC.
                                  (Former Name)


               Texas                        76-0510754
               -------                      ----------
        (State of incorporation)            (I.R.S. Employer
                                            Identification No.)

            7010 NW 100 DRIVE, BLDG. A, STE. #101, HOUSTON, TX 77092
            ---------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (713) 939-1833


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2)  has  been  subject  to the  filing
requirements for at least the past 90 days.

                                Yes  X     No
                                   -----     -----

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

                  12,517,868 common shares as of September 30, 2000


<PAGE>



Part I:  FINANCIAL INFORMATION

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)

<PAGE>
<TABLE>
<CAPTION>



PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET - UNAUDITED
<S>                                                                     <C>                          <C>

                                                                                 September 30, 2000     December 31, 1999
                                                                          --------------------------   -------------------
ASSETS
CURRENT ASSETS
    Cash and cash equivalents                                           $                   129,209  $        24,135
    Employee receivables                                                                      2,158            2,158
    Receivable from parent company                                                                            13,185
    Other receivables                                                                                            270
                                                                          --------------------------   -----------------
Total current assets                                                                        131,367           39,748

PROPERTY AND EQUIPMENT, at cost                                                             142,533          131,361
    Less: Accumulated depreciation                                                          (86,723)         (67,848)
                                                                          --------------------------   -----------------
                                                                                             55,810           65,513

OTHER ASSETS
    Deposits                                                                                 10,000
    Patent costs                                                                             59,459           44,699
    Less: Accumulated amortization                                                           (8,058)          (6,039)
    Other assets                                                                                300              300
                                                                          --------------------------   -----------------
                                                                                             61,701           38,960
                                                                          --------------------------   -----------------
                                                                        $                   248,878          142,221
                                                                          ==========================   =================

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
    Trade accounts payable and accrued expenses (Note 8)                $                 1,497,051        1,116,412
    Due to shareholder                                                                       46,651           87,290
                                                                          --------------------------   -----------------
Total current liabilities                                                                 1,543,702        1,253,702

SHAREHOLDERS' EQUITY
    Common stock, $.001 par value,
      authorized 20,000,000 shares,
      issued and outstanding 13,323,868 shares
      stock subscribed but not issued 1,128,283 shares
      (Note 6)                                                                               15,114           10,543
    Additional paid in capital                                                            1,741,906        1,248,394
    Deficit accumulated during the development stage                                     (3,051,844)      (2,370,418)
                                                                          --------------------------   -----------------
Total shareholders' equity                                                               (1,294,824)      (1,111,481)
                                                                          --------------------------   -----------------
                                                                        $                   248,878          142,221
                                                                          ==========================   =================

</TABLE>

See notes to financial statements.



<PAGE>
<TABLE>
<CAPTION>


PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS AND ACCUMULATED DEFICIT - UNAUDITED

<S>                                                                <C>                 <C>

                                                                                            August 5, 1996
                                                                      Nine months ended         through
                                                                      September 30, 2000   September 30, 2000
                                                                     ----------------    -------------------------

Revenues                                                           $               0   $                    1,850
Direct costs                                                                       0                            0
                                                                     ----------------    -------------------------
Gross profit                                                                       0                        1,850

Administrative and general expenses                                          660,052                   2,946,194
Depreciation expense                                                          18,875                       86,723
                                                                     ----------------    -------------------------
                                                                             678,927                    3,032,917
                                                                     ----------------    -------------------------
Loss from operations                                                        (678,927)                  (3,031,067)

Other income                                                                                                4,800
Interest expense                                                              (2,499)                     (25,577)
                                                                     ----------------
                                                                     ----------------    -------------------------
                                                                              (2,499)                     (20,777)
                                                                     ----------------    -------------------------
Loss before income taxes                                                    (681,426)                  (3,051,844)
Federal income taxes - current expense (benefit)                                   0                            0
                                                                     ----------------    -------------------------
Net loss                                                                    (681,426)                  (3,051,844)

Accumulated deficit at beginning of period                                 2,370,418                           0
                                                                     ----------------    -------------------------
Deficit accumulated during the development stage                   $      (3,051,844)  $               (3,051,844)
                                                                     ================    =========================
Loss per share                                                                 ($.44)

</TABLE>




See notes to financial statements.




<PAGE>
<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS - UNAUDITED
<S>                                                                  <C>                          <C>


                                                                                                                From
                                                                                                           August 5, 1996
                                                                                  3Q                          through
                                                                                 2000                    September 30, 2000
                                                                       -------------------------    -----------------------------
OPERATING ACTIVITIES
Net loss                                                             $                 (171,940)  $                   (3,051,844)
Adjustments to reconcile net loss to net cash
   provided by (used in) operating activities:
      Depreciation and amortization                                                       7,467                           94,781
      Changes in operating assets and liabilities:
         Receivable from parent                                                   -                                       13,185
         Deposits                                                                       (10,000)                         (10,000)
         Patent costs                                                                    (1,000)                         (15,030)
         State tax refund receivable                                              -                                      (44,429)
         Trade accounts payable and accrued expenses                                     88,703                        1,497,201
                                                                       -------------------------    -----------------------------
Net cash (used in) operating activities                                                 (86,770)                      (1,516,136)

INVESTING ACTIVITIES
Capital expenditures                                                                     (2,194)                        (142,533)
Other assets                                                                      -                                         (300)
Related parties                                                                   -                                      (15,343)
                                                                       -------------------------    -----------------------------
Net cash (used in) investing activities                                                  (2,194)                        (158,176)

FINANCING ACTIVITIES
Principal payments on long-term debt                                                     (7,900)                         (45,236)
Related parties                                                                   -                                       91,887
Proceeds from issuance of stock                                                         226,073                        1,756,870
                                                                       -------------------------    -----------------------------
Net cash provided by financing activities                                               218,173                        1,803,521
                                                                       -------------------------    -----------------------------
INCREASE IN CASH                                                                        129,209                          129,209
Cash and cash equivalents at beginning of period                                  -                              -
                                                                       -------------------------
                                                                       -------------------------    -----------------------------
Cash and cash equivalents at end of period                           $                  129,209   $                      129,209
                                                                       =========================    =============================

</TABLE>


See notes to financial statements.

<PAGE>
<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF SHAREHOLDERS' EQUITY - UNAUDITED
For the Period August 5, 1996 (Inception) through September 30, 2000

<S>                                                       <C>            <C>                   <C>        <C>           <C>


                                                                                                                   Deficit
                                                                                                                 Accumulated
                                                                                                Additional        During the
                                                                     Common                      Paid in         Development
                                                                     Stock                      Capital (3)          Stage     Total
                                                           -------------------------------------------------------------------------

Issuance of 4,000,000 shares - August 7, 1996              4,000,000     $      4,000          $          $                  4,000
Issuance of 77,320 shares - January 23, 1997                  77,320               77              9,923                     10,000
Issuance of 300,000 shares - January 23, 1997                300,000              300                                           300
Issuance of 86,800 shares - Various dates in 1997             86,800               87             35,118                     35,205
Issuance of 480,000 shares - Various dates in 1997           480,000              480            254,520                    255,000
Net loss for the period August 5, 1996 (Inception)
  through July 31, 1997                                                                                       (325,680)    (325,680)
                                                          --------------------------------------------------------------------------
Balance at July 31, 1997                                   4,944,120            4,944            299,561      (325,680)     (21,175)
Issuance of 970,193 shares - Various dates in 1998           970,193              970            417,927                    418,897
Repurchase of 225,000 shares - Various dates in 1998         225,000)            (225)           (99,775)                  (100,000)
Issuance of 129,500 shares - Various dates in 1998           129,500              130             18,390                     18,520
Reduction of paid in capital for management fees                                                  (8,377)                    (8,377)
Net loss for the year ended July 31, 1998                                                                     (778,556)    (778,556)
                                                          --------------------------------------------------------------------------
Balance at July 31, 1998                                   5,818,813            5,819            627,726    (1,104,236)    (470,691)
Issuance of 178,000 shares - Various dates in 1998           178,000              178             72,372                     72,550
Repurchase of 73,000 shares - Various dates in 1998          (73,000)             (73)            (5,227)                    (5,300)
Issuance of 43,000 shares - Various dates in 1998             43,000               43             87,442                      87,485
Reduction of paid in capital for management fees                                                 (16,215)                   (16,215)
Net loss for 5 months ended December 31, 1998                                                                 (403,184     (403,184)
                                                          --------------------------------------------------------------------------
Balance at December 31, 1998                               5,966,813            5,967            766,098    (1,507,420)    (735,355)
Issuance of 4,576,555 shares - Various dates in 1999       4,576,555            4,576            482,296                    486,872
Net loss for the year ended December 31, 1999                                                                 (862,998)    (862,998)
                                                          --------------------------------------------------------------------------
Balance at December 31, 1999                              10,543,368     $     10,543  $       1,248,394   $(2,370,418) $(1,111,481)
Issuance of 1,974,500 shares and 1,184,283 shares
 subscribed but not yet issued - Various dates
  in 1Q00 (Note 6)                                         3,158,783            3,159            268,701                    271,860
Net loss 1Q2000                                                                                               (288,774)    (288,774)
                                                          --------------------------------------------------------------------------
Balance at March 31, 2000                                 13,702,151           13,702          1,517,095    (2,659,192)  (1,128,395)
Issuance of 260,000 shares - June 21, 2000                   260,000              260                                           260
Cancellation of 200,000 shares issued in a prior
  quarter                                                   (200,000)            (200)                                         (200)
Issuance of 90,000 shares for services rendered               90,000               90                                            90
Net Loss 2Q2000                                                                                               (220,712)    (220,712)
                                                          --------------------------------------------------------------------------
Balance at June 30, 2000                                  13,852,151           13,852          1,517,095    (2,879,904)  (1,348,957)
Shares subscribed but not issued - Various dates
  in 3Q00                                                  1,262,000            1,262            224,811                    226,073
Net Loss 3Q2000                                                                                               (171,940)    (171,940)
                                                          --------------------------------------------------------------------------
Balance at September 30, 2000                             15,114,151           15,114          1,741,906    (3,051,844)  (1,294,824)
                                                          ==========================================================================
</TABLE>

(1) See Note 5 to the financial statements.
(2)  Stock  issued  in  exchange  for legal  expenses,  administrative  fees and
commissions relating to the stock offering.
(3) Stock issue costs deducted from  additional  paid in capital  related to the
offering/sale totaled $53,697.

<PAGE>


PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - UNAUDITED
September 30, 2000

Note 1 - Organization and Business Activity

Pathobiotek  Diagonstics,  Inc.,  (the  "Company")  was formed on August 5, 1996
under the laws of the State of Texas for the purpose of  developing,  producing,
distributing,  selling  and/or  performing  diagnostics  for  various  virus and
bacterium.  The Company is a  developmental  stage  company  under  Statement of
Financial  Accounting  Standard  ("SFAS") No 7,  "Accounting  and  Reporting  by
Development State Enterprises".  Pathobiotek Diagnostics,  Inc. was a subsidiary
of Pacific Biotech International, Inc. (the "Parent"), a Texas Corporation until
May 16, 2000, Pacific Biotech  International,  Inc. no longer owns any shares of
the Company.  On March 6, 2000, the Company completed a Share Purchase Agreement
with  shareholders  of  Investra  Enterprises,  Inc.  (IEI) in which the Company
acquired all 672,000  issued and  outstanding  shares of IEI for  $150,000]  for
purposes  of  completing  a merger  of the  Company  IEI.  The  Company  was the
surviving entity.

Note 2 - Summary of Significant Accounting Policies

Cash and Cash Equivalents:
--------------------------
The Company  considers all highly liquid  investments  with  maturities of three
months or less when purchased to be cash equivalents.

Supplemental schedule of non-cash investing and financing activities:  Equipment
totaling $91,887 was acquired through a note payable financing agreement.

Property and Equipment:
-----------------------
Property and equipment,  consisting primarily of lab and computer equipment,  is
stated at cost.  Depreciation  is computed using the  straight-line  method over
estimated lives ranging from 5 to 7 years.

Maintenance   and  repairs  are  expensed  as  incurred;   major   renewals  and
improvements are capitalized.

Use of Estimates:
-----------------

Management  uses estimates and  assumptions in preparing  financial  statements.
Those  estimates  and  assumptions  affect the reported  revenues and  expenses.
Actual results could differ from the estimates.

<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - UNAUDITED - Continued
September 30, 2000

Concentration of Credit Risk:
-----------------------------
The Company's financial instruments that are subject to concentrations of credit
risk  consist of cash.  The  Company  places its cash in a high  credit  quality
institution. At some times, such balances may be in excess of the FDIC insurance
limits.

Asset Valuation:
----------------
The carrying  amounts of  long-lived  assets are reviewed  periodically.  If the
asset carrying amount is not recoverable, the asset is considered to be impaired
and the value is adjusted.

Amortization of Patent Related Costs:
-------------------------------------
In  connection  with the issuance of shares of stock to the parent (Note 5), the
Company was assigned and licensed  all  technological  applications  of one U.S.
Patent  Application.  Legal  costs  related to the  application  incurred by the
Company  are  capitalized  in  accordance  with   management's   estimation  and
expectation of securing a patent.

Capitalized patent related costs are amortized on a straight-line basis over the
expected life of the patent starting from the application date.

The patent  process may take from several  months to several  years.  Should the
patent be denied or its value impaired, the balance of unamortized costs will be
expensed at that date.

Income Taxes:
-------------
The  Company  utilizes  Statement  of  Financial  Accounting  Standard  No. 109,
"Accounting for Income Taxes" ("SFAS 109"). Under SFAS 109, the liability method
is used in accounting for income taxes.  Under this method,  deferred tax assets
and liabilities are determined based on differences  between financial reporting
and tax  bases of assets  and  liabilities  and are  measured  sing the  enacted
statutory  tax  rates  and laws that  will be in  eff3ect  when the  differences
reverse.

Fair Value of Financial Instruments:
------------------------------------
The carrying amounts of cash,  receivables,  and payables approximate their fair
values due to the short-term maturities of these instruments.

<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - UNAUDITED - Continued
September 30, 2000

Note 3 - Note Payable - Related Party

In  connection  with the purchase of lab  equipment and supplies from the Parent
totaling $91,887,  the Company entered into a promissory note payable agreement.
The  remaining  balance of $43,651 and any unpaid  interest was due on or before
maturity of July 31, 2000. The note is secured by the lab  equipment.  Effective
May 16, 2000,Pacific Biotech International, Inc. transferred the note receivable
to the President of the Company.

Note 4 - Income Taxes

The Company has incurred net operating losses of $3,051,844 since inception.  No
tax benefit has been recorded  relating to these losses  because  realization of
the carryforward benefit is uncertain.  For tax purposes, the net operating loss
carryforwards will expire beginning in the year 2012.

Note 5 - Related Party Transactions

On August 7, 1996, the Company issued  4,000,000  shares of stock to the Parent,
Pacific Biotech  International,  Inc.,  exchange for certain  intangible  assets
consisting  primarily  of licenses  rights and  technological  applications.  In
accordance with APB 16 and 29, the exchange was recorded at the Parent company's
historical  capitalized  basis,  which was not considered  material at August 7,
1996.

In March 1999, the Company issued an additional 2,000,000 shares of stock to the
Parent in  exchange  for  certain  intangible  assets as  described  above.  The
exchange  was recorded at the Parent  company's  historical  capitalized  basis,
which was not considered material at March 1999. An additional  2,000,000 shares
was due to the Parent as of March 31, 2000.  The right to receive the  2,000,000
shares was transferred to two executives of the Company  effective May 16, 2000.
This  exchange  will not  have a  material  affect  on the  Company's  financial
position.

<PAGE>


PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS - UNAUDITED - Continued
September 30, 2000

Note 6 - Subscribed Stock

In  addition  to the  2,000,000  shares  due to two  executives  related  to the
transfer of stock from the former Parent (Note 5) and the 3,110,25 shares due to
executives  of the company for  compensation  (Note 8), at  September  30, 2000,
there were 1,790,283 shares subscribed but not yet issued.

Note 7- Leases

The Company leases office space and certain  equipment under  operating  leases.
Future minimum lease payments are as follows:



                                     Year
                                     Ended
                                     December 31,
                                     ------------
                                       2000        $       9,266
                                       2001                  725
                                                   -------------
                                                           9,991
                                                   =============

Rent expense for the quarter ended September 30, 2000, was $5,453.
Rent expense from August 5, 1996 through September 30, 2000, was $119,383.

Note 8 - Stock-Based Compensation

Stock-based  compensation  plans are  accounted  for using the  intrinsic  value
method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees."  Under this method,  compensation cost is recognized
based on the fair value at the grant  dates for awards  under those  plans.  The
accompanying  financial statements include compensation costs of $82,031 for the
quarter ended  September 30, 2000,  and $1,166,484 for the period from August 5,
1996 (Inception)  through September 30, 2000,  representing a total of 3,110,625
shares due for stock-based compensation.


<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL  CONDITION AND RESULTS
OF OPERATIONS

RESULTS OF  OPERATIONS  FOR THE NINE MONTHS ENDED SEPT. 30, 2000

The Company is in the  development  stage and had no revenues for the nine month
period ended  September 30, 2000 but incurred  expenses  totalling  $678,927 and
interest  cost of $2,499.  The net loss of the nine month period was  ($681,426)
and the per share loss was ($.44).

The Company has had minimal  revenues  since  inception in August 1996,  but has
incurred  $3,031,067 in expenses  during the period since inception to September
30, 2000, for a net loss, including interest costs of $20,777O,  of ($3,051,844.
The Company expects the trend of losses to continue in the forseeable future due
to the lack of developed, marketable products or technology.

RESULTS OF OPERATIONS FOR THE QUARTER ENDED SEPTEMBER 30, 2000

The Company had no revenues in the quarter ended September 30, 2000 but incurred
operating  expenses of $171,515 and interest expenses of $425. The Company had a
net loss of ($171,940) for the quarter.  The Company is in the development stage
and has had only $1,850 in revenues since  inception in August 1996. The Company
has  incurred  $3,031,067  in  expenses  during the period  since  inception  to
September  30, 2000 for a net loss,  including  interest  costs of  $20,777,  of
($3,051,844).

The Company loss per share for the quarter was ($.20).  The Company  expects the
trend  of  losses  to  continue  in the  forseeable  future  due to the  lack of
developed, marketable products or technology.

LIQUIDITY AND CAPITAL RESOURCES

The Company had $129,209 in cash  capital at the end of the period.  The Company
has current  liabilities  in the amount of $1,497,051  consisting of $330,567 in
accounts payable and $1,166,484 in deferred executive  compensation,  at the end
of the  period  with  the  result  of a net  deficit  in  operating  capital  of
($1,367,842).  The  Company  will be  forced to  either  borrow or make  private
placements of stock in order to fund  operations.  No assurance exists as to the
ability to achieve loans or make private placements of stock.

<PAGE>


                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

        None

ITEM 2. CHANGES IN SECURITIES

        None

ITEM 3. DEFAULT UPON SENIOR SECURITIES

        None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

        None

ITEM 5. OTHER INFORMATION

        None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

        None



<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Date: November 21, 2000

                                    PATHOBIOTEK



                                    /s/ Robert Simpson
                                    --------------------------
                                    Robert Simpson, President